Financial Summary for the Third Quarter of Fiscal Year Ending March 2026 [Japanese GAAP] (Consolidated)

Performance Overview

During the cumulative third quarter period of the fiscal year ending March 2026 (April 1, 2025 to December 31, 2025), net sales amounted to ¥20,611 million (6.8% increase YoY), operating income was ¥2,478 million (5.5% increase YoY), ordinary income was ¥2,859 million (8.6% increase YoY), and net income attributable to owners of parent for the quarter was ¥2,039 million (9.1% increase YoY). The increase in net sales reflects growth in both the pharmaceutical and building materials businesses, with the pharmaceutical business benefitting particularly from a recovery in shipments in the electronics industry and improved performance of overseas subsidiaries. Meanwhile, the equity ratio declined from 85.6% at the end of the same period last year to 84.0%.

Segment Performance and Dividend Status

The pharmaceutical business recorded net sales of ¥17,680 million (7.3% increase YoY) and segment profit of ¥2,787 million (8.8% increase YoY). The building materials business posted net sales of ¥2,931 million (4.2% increase YoY) and segment profit of ¥446 million (5.3% decrease YoY), impacted by a decline in new housing starts and a challenging business environment. Regarding dividends, the annual dividend forecast for fiscal 2026 is ¥90 (up from ¥75 last year), with a payment of ¥45 planned at the end of the second quarter.